The impact of alcohol dependence on HCV treatment initiation in HIV / HCV co-infected patients

Prochno KW, Aaronson CJ, Cervantes L, Georgi M, Miller TR, Mhango G, Weiss JJ

The Icahn School of Medicine at Mount Sinai



No disclosures



Randomized controlled trial of HIV / HCV individuals
N = 83 consented, N = 53 randomized / not excluded
Active intervention: RN-administered, using the Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) and MI and CBT techniques

4 one-hour sessions over the course of 1 month

- Attention control condition: RN-administered HIV education
- Primary outcome: HCV treatment initiation on DAA ≤ 6 months from randomization

Criteria

INCLUSION

- HIV / HCV co-infected
- ≥ 21 YO
- English or Spanish as primary language
- Two most recent HIV viral loads both < 1000 copies/mL</p>
- ≤ 6 months since last attended HIV PCP appointment
- > 12 months since last attended HCV provider appointment

EXCLUSION

- Active malignancy
- CKD on dialysis
- Decompensated cirrhosis

Baseline characteristics

Variable	PREP-C condition (n=28)	Control condition (n=25)	p-value
Age, years, mean ± SD	53.4 ± 8.6	54.6 ± 10.1	.64
Male, n (%)	21 (75.0)	17 (68.0)	.57
Race/ethnicity, n (%)			.91
White	3 (60.0)	2 (40.0)	
Black	11 (50.0)	11 (50.0)	
Hispanic	14 (53.8)	12 (46.2)	
Other	0 (0.0)	0 (0.0)	
Monthly income, USD, mean ± SD	1032 ± 582	1038 ± 445	.76
Education, years, mean ± SD	11.8 ± 2.3	11.6 ± 2.6	.87
Medicaid as primary insurance, n (%)	22 (78.6)	19 (76.0)	.82
English as primary language, n (%)	20 (71.4)	19 (76.0)	.71
AIDS diagnosis, n (%)	16 (57.1)	19 (76.0)	.15

Baseline characteristics

Variable	PREP-C condition (n=28)	Control condition (n=25)	p-value
Global cognition T-score, mean ± SD (trails A/B + SDMT + WCST)	40.8 ± 8.0 (n=25)	44.5 ± 5.9 (n=20)	.087
FIB-4 score, n (%)			.84
< 1.45	10 (35.7)	7 (28.0)	
1.45 - 3.25	13 (46.4)	13 (52.0)	
> 3.25	5 (17.9)	5 (20.0)	
HCV treatment naïve, n (%)	18 (64.3)	21 (84.0)	.10
IVDU history, n (%)	18 (64.3)	12 (48.0)	.23
SCID lifetime dependence, n (%)			
Alcohol	13 (46.4)	12 (48.0)	.56
Marijuana	5 (17.9)	4 (16.0)	1.00
Stimulants	5 (17.9)	4 (16.0)	1.00
Opioids	16 (57.1)	9 (36.0)	.12
Cocaine	20 (71.4)	17 (68.0)	1.00
Psychiatric diagnosis, n (%)	19 (67.9)	20 (80.0)	.32

Findings

 Significant negative association between treatment initiation and lifetime history of alcohol dependence

X² (1) = 4.83, p = .028

 No association between treatment initiation and non-alcohol substance dependence

- Stimulants: X² (1) = 1.15, p = .46
- Opioids: X² (1) = 0.26, p = .61
- Cocaine: X² (1) = 1.03, p = .31

 Binomial regression model comprising demographics, treatment group, and alcohol dependence status was significant (p < .001)

Patients with alcohol dependence were 0.13 times as likely to initiate treatment as those without, even when controlling for intervention
OR 0.13, 95% CI [0.03, 0.71]; p = .018

Conclusions

- Lifetime diagnosis of Alcohol Dependence remains a significant barrier to HIV patients initiating HCV treatment
- Lifetime diagnosis of other substance dependencies were not barriers

Research should further examine the uniqueness of alcohol persisting as a barrier in terms of provider perceptions, insurance restrictions, and patient-level factors for persons with HIV / HCV coinfection

Acknowledgements

- Research reported in this presentation was supported by the National Institute of Mental Health of the National Institutes of Health under award number R34MH099930
- The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.